In vivo/in vitro pharmacokinetic and pharmacodynamic study of spray-dried poly-(dl-lactic-co-glycolic) acid nanoparticles encapsulating rifampicin and isoniazid.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  International journal of pharmaceutics

• Publication date

  2013-02-28

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ijpharm.2013.01.038PMID 23357255
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of protein binding on the biodistribution of PEGylated PLGA nanoparticles post oral administration.

  2012cited by this paper
• The immune effects of naturally occurring and synthetic nanoparticles.

  2010cited by this paper
• In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles.

  2010cited by this paper
• In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems.

  2010cited by this paper
• Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy.

  2009cited by this paper
• Nanotechnology, nanotoxicology, and neuroscience.

  2009cited by this paper
• Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles.

  2009cited by this paper
• Targeted delivery of nanoparticles for the treatment of lung diseases.

  2008cited by this paper
• Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs.

  2008influential reference
• Biocompatible mesoporous silica nanoparticles with different morphologies for animal cell membrane penetration

  2008cited by this paper
• Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles.

  2008cited by this paper
• Foreign body reaction to biomaterials.

  2008cited by this paper
• Pharmacokinetics and biodistribution of nanoparticles.

  2008influential reference
• Preparation of Alendronate Liposomes for Enhanced Stability and Bioactivity: In Vitro and In Vivo Characterization

  2008cited by this paper
• Detailed identification of plasma proteins adsorbed on copolymer nanoparticles.

  2007cited by this paper
• Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis.

  2007cited by this paper
• Preparation and characterization of mucoadhesive polymer-coated nanoparticles.

  2006influential reference
• Nanotechnology: Intelligent Design to Treat Complex Disease

  2006cited by this paper
• Determinants of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol Pharmacokinetics in a Cohort of Tuberculosis Patients

  2006cited by this paper
• Preparation and physical characterization of a novel marine oil emulsion as a potential new formulation vehicle for lipid soluble drugs.

  2006influential reference
• Rapid Microbiologic and Pharmacologic Evaluation of Experimental Compounds against Mycobacterium tuberculosis

  2006cited by this paper
• Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses.

  2006cited by this paper
• Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System

  2006cited by this paper
• Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems.

  2005cited by this paper
• Nanomedicine gets clinical

  2005cited by this paper
• Cytometric bead array: a multiplexed assay platform with applications in various areas of biology.

  2004cited by this paper
• Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin.

  2004cited by this paper
• Uptake of polystyrene beads bearing functional groups by macrophages and fibroblasts

  2004cited by this paper
• Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties.

  2003cited by this paper
• Understanding endocytic pathways and intracellular trafficking: a prerequisite for effective design of advanced drug delivery systems.

  2003cited by this paper
• Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.

  2002cited by this paper
• Targeting to macrophages: role of physicochemical properties of particulate carriers--liposomes and microspheres--on the phagocytosis by macrophages.

  2002cited by this paper
• Immunomodulating activities of soluble synthetic polymer-bound drugs.

  2002cited by this paper
• Size-dependent proinflammatory effects of ultrafine polystyrene particles: a role for surface area and oxidative stress in the enhanced activity of ultrafines.

  2001influential reference
• The effect of surface coverage and conformation of poly(ethylene oxide) (PEO) chains of poloxamer 407 on the biological fate of model colloidal drug carriers.

  2001cited by this paper
• Biomaterials in drug delivery and tissue engineering: one laboratory's experience.

  2000cited by this paper
• The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices.

  2000cited by this paper
• 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption.

  2000cited by this paper
• Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.

  1999cited by this paper
• The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency.

  1999cited by this paper
• The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency.

  1999cited by this paper
• Evaluation of Once-Weekly Therapy for Tuberculosis Using Isoniazid plus Rifamycins in the Mouse Aerosol Infection Model

  1998cited by this paper
• In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein.

  1996cited by this paper
• The leukocyte integrin gene CD11c is transcriptionally regulated during monocyte differentiation.

  1995cited by this paper
• Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs

  1995cited by this paper
• Which polymers can make nanoparticulate drug carriers long-circulating?

  1995cited by this paper
• Long circulating microparticulate drug carriers

  1995cited by this paper
• Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection.

  1993cited by this paper
• Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages.

  1992cited by this paper
• Nanoparticle Uptake by the Rat Gastrointestinal Mucosa: Quantitation and Particle Size Dependency

  1990cited by this paper
• Three-dimensional structure of human serum albumin.

  1989cited by this paper
• Bioavailability and disposition kinetics of rifampicin capsules.

  1988cited by this paper
• Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth

  1986cited by this paper
• Adverse effects of rifampin.

  1983cited by this paper
• Plasma Protein Binding of Drugs in Pregnancy

  1982cited by this paper
• [Adverse effects of rifampicin].

  1973cited by this paper
• Effect of Isoniazid on the In Vivo Mycolic Acid Synthesis, Cell Growth, and Viability of Mycobacterium tuberculosis

  1972cited by this paper
• Rifampicin: a new orally active rifamycin.

  1966cited by this paper

• Mannosylated chitosan-decorated PLGA nanoparticles for targeted pulmonary delivery of isoniazid: a promising approach in the treatment of tuberculosis

  2025cites this paper
• Multifunctional PLGA nanosystems: enabling integrated diagnostic and therapeutic strategies

  2025cites this paper
• A Review of the Potential of Poly-(lactide-co-glycolide) Nanoparticles as a Delivery System for an Active Antimycobacterial Compound, 7-Methyljuglone

  2024cites this paper
• Pichia pastoris-Derived β-Glucan Capsules as a Delivery System for DNA Vaccines

  2024cites this paper
• Inhalational Delivery of β‐glucan‐chitosan‐poly(lactic co‐glycolic) acid Nanoparticles Enhance Alveolar Macrophage Rifampin Concentrations for the Treatment of Tuberculosis

  2024cites this paper
• Designing Pediatric Nano-formulations Faces a slew of Obstacles: A Review

  2024cites this paper
• Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles

  2022cites this paper
• Nanoencapsulated Lippia rotundifolia antimicrobial peptide: synthesis, characterization, antimicrobial activity, and cytotoxicity evaluations

  2022cites this paper
• Synthesis of nanoparticles of the chitosan-poly((α,β)-DL-aspartic acid) polyelectrolite complex as hydrophilic drug carrier

  2022cites this paper
• Isoniazid Nano-drug Delivery Systems Targeting Macrophages for the Treatment of Tuberculosis

  2022cites this paper
• Production and Characterization of Antituberculostatic Drug-Loaded Nanofibers by Electrospinning Method

  2022cites this paper
• Nanotechnology and tuberculosis: An old disease with new treatment strategies.

  2022cites this paper
• Alendronate sodium-polymeric nanoparticles display low toxicity in gastric mucosal of rats and Ofcol II cells.

  2021cites this paper
• New Perspectives in Drug Delivery Systems for the Treatment of Tuberculosis.

  2021cites this paper
• Challenges And Opportunities Of Nanotechnological Based Approach For The Treatment Of Tuberculosis.

  2021cites this paper
• Microfluidics-based encapsulation of isoniazid in egg white/carrageenan microparticles for sustained release

  2021cites this paper
• Stabilization by Nano Spray Dryer of Pioglitazone Polymeric Nanosystems: Development, In Vivo, Ex Vivo and Synchrotron Analysis

  2021cites this paper
• Nanomedicines in Tuberculosis: Diagnosis, Therapy and Nanodrug Delivery

  2020cites this paper
• Release kinetics of fluorescent dyes from PLGA nanoparticles in retinal blood vessels: in vivo monitoring and ex vivo localization.

  2020cites this paper
• Integrative Nanomedicine for New Therapies

  2020cites this paper
• Engineering materials

  2020cites this paper
• Pulmonary Delivery of Linezolid Nanoparticles for Treatment of Tuberculosis: Design, Development, and Optimization

  2020cites this paper
• Development and Optimization of Inhalable Levofloxacin Nanoparticles for The Treatment of Tuberculosis.

  2020cites this paper
• Pulmonary Delivery of Linezolid Nanoparticles for Treatment of Tuberculosis: Design, Development, and Optimization

  2020cites this paper
• Towards a Continuous Manufacturing Process of Protein-Loaded Polymeric Nanoparticle Powders

  2020cites this paper
• Pharmacokinetics and in vivo distribution of optimized PLGA nanoparticles for pulmonary delivery of levofloxacin

  2020influential citation
• Intramacrophage delivery of dual drug loaded nanoparticles for effective clearance of Mycobacterium tuberculosis.

  2020cites this paper
• Recent Progress in the Development of Poly(lactic-co-glycolic acid)-Based Nanostructures for Cancer Imaging and Therapy

  2019cites this paper
• Nanomedicines as Drug Delivery Carriers of Anti-Tubercular Drugs: From Pathogenesis to Infection Control

  2019cites this paper
• Matryoshka-type gastro-resistant microparticles for the oral treatment of Mycobacterium tuberculosis.

  2019cites this paper
• Alginate modified-PLGA nanoparticles entrapping amikacin and moxifloxacin as a novel host-directed therapy for multidrug-resistant tuberculosis

  2019cites this paper
• Influence of PEGylation on PLGA nanoparticle properties, hydrophobic drug release and interactions with human serum albumin

  2019cites this paper
• Spray-Dried, Nanoencapsulated, Multi-Drug Anti-Tuberculosis Therapy Aimed at Once Weekly Administration for the Duration of Treatment

  2019cites this paper
• Formulation and biological evaluation of nanomedicins with Cenizo Leucophyllum frutescens (BERL.) I.M. JOHNSTON (Scrophulariaceae) extract against Mycobacterium tuberculosis

  2019cites this paper
• Therapeutic Management of Pulmonary Tuberculosis by Mannosylated Chitosan Ascorbate Microspheres: Preparation and Characterization

  2019cites this paper
• How cells die

  2018cites this paper
• The development and evaluation of a novel hybrid PLGA nanoparticle-Pheroid® with the potential to improve tuberculosis therapy

  2018cites this paper
• Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead

  2018cites this paper
• Development and In Vitro Release of Isoniazid and Rifampicin-Loaded Bovine Serum Albumin Nanoparticles

  2018cites this paper
• Study of dual encapsulation possibility of hydrophobic and hydrophilic drugs into a nanocarrier based on bio-polymer coated graphene oxide using density functional theory, molecular dynamics simulation and experimental methods

  2018cites this paper
• Novel nanoparticle delivery systems for rifampicin: an effective strategy against tuberculosis?

  2017cites this paper
• Physicochemical effects of lactose microcarrier on inhalation performance of rifampicin in polymeric nanoparticles

  2017cites this paper
• Nanocarrier-Assisted Antimicrobial Therapy Against Intracellular Pathogens

  2017cites this paper
• Critical physicochemical and biological attributes of nanoemulsions for pulmonary delivery of rifampicin by nebulization technique in tuberculosis treatment

  2017cites this paper
• Synthesis and characterization of acetylated amylose and development of inclusion complexes with rifampicin.

  2017cites this paper
• System with embedded drug release and nanoparticle degradation sensor showing efficient rifampicin delivery into macrophages.

  2017cites this paper
• Pharmacokinetic and Pharmacodynamic evaluation of Camptothecin encapsulated Poly (methacylic acid-co-methyl methacrylate) nanoparticles -

  2017cites this paper
• Pharmacokinetics and Pharmacodynamics (PK/PD) of Bionanomaterials

  2016cites this paper
• Mikroemulsionen: neue Möglichkeiten zur Erweiterung der Synthese anorganischer Nanopartikel

  2016cites this paper
• The formulation of nanomedicines for treating tuberculosis.

  2016cites this paper
• Preparation and Loading with Rifampicin of Sub-50 nm Polyethyl cyanoacrylate Nanoparticles by Semicontinuous Heterophase Polymerization

  2016cites this paper
• Pharmacokinetic study of furosemide incorporated PLGA microspheres after oral administration to rat

  2016cites this paper
• Improving Treatment of Mycobacterial Infections

  2016cites this paper
• Synthesis and characterization of the antitubercular phenazine lapazine and development of PLGA and PCL nanoparticles for its entrapment.

  2016cites this paper
• The relevancy of controlled nanocrystallization on rifampicin characteristics and cytotoxicity

  2016cites this paper
• Microemulsions: Options To Expand the Synthesis of Inorganic Nanoparticles.

  2016cites this paper
• Nanotechnology-Based Drug Delivery Systems for Treatment of Tuberculosis--A Review.

  2016cites this paper
• Dry powder inhalable formulations for anti-tubercular therapy.

  2016cites this paper
• Spray drying strategies to stop tuberculosis

  2016cites this paper
• Isoniazid@Fe2O3‐Nanocontainer mit antibakterieller Wirkung auf Tuberkulose‐Mykobakterien

  2015cites this paper
• Inhaled dry powder formulations for treating tuberculosis.

  2015cites this paper
• Inhaled formulations and pulmonary drug delivery systems for respiratory infections.

  2015cites this paper
• Isoniazid@Fe2 O3 Nanocontainers and Their Antibacterial Effect on Tuberculosis Mycobacteria.

  2015cites this paper
• Infectious Diseases: Need for Targeted Drug Delivery

  2014cites this paper
• Pulmonary multifunctional nano-oncological modules for lung cancer treatment and prevention.

  2014cites this paper
• Nanomedicines in the future of pediatric therapy.

  2014cites this paper
• Preparação e Caracterização de Nanocápsulas Furtivas e Sítio-específicas Para o Tratamento do Câncer

  2013cites this paper
• State of the art and future directions in nanomedicine for tuberculosis

  2013cites this paper
• Formation and characterization of chitosan-polylacticacid-polyethylene glycol-gelatin nanoparticles: a novel biosystem for controlled drug delivery.

  2013cites this paper
• ormation and characterization of hitosan-polylacticacid-polyethylene glycol-gelatin nanoparticles : novel biosystem for controlled drug delivery

  2013cites this paper
• Digital Commons @ University of South Florida Digital Commons @ University of South Florida

  year unknowncites this paper
• Journal of Drug Delivery and Therapeutics

  year unknowncites this paper